Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs

This article was originally published in PharmAsia News

Executive Summary

BEIJING - One year after adulterated heparin sourced from China began triggering scores of adverse reactions and deaths in U.S. patients, U.S. FDA is preparing to launch a voluntary pilot program aimed at helping prevent contaminated drugs from entering the country

You may also be interested in...



FDA May Require Drug Importers To Verify Product Quality

Public meeting will solicit stakeholder comments on how FDASIA-mandated import regulations should be implemented as the expedited entry program reemerges.

IOM Pushes For FDA Collaboration With Foreign Regulators

In a report on how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad, the Institute of Medicine recommends the agency provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.

IOM Pushes For FDA Collaboration With Foreign Regulators

In a report on how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad, the Institute of Medicine recommends the agency provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.

Related Content

UsernamePublicRestriction

Register

SC070777

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel